Press
If you would like to discuss anything press related, please email rarecan@ovidhealth.co.uk
RareCan in the News
National Health Executive – 24 January 2022 – Digitalisation of Clinical Trials
Novopath – 9 December 2021 – Novopath & RareCan Research and Innovation Collaboration
Newcastle Chronicle – 25 November – Inside the Newcastle ‘BioBank’ of blood and tissue samples which could help cure rare cancers
Drug Discovery World – 23 November – Accelerating Research: The Path Forward for Treating Rare Cancers
Adlib Recruitment – 19th November – Product People Potential – Our Chat with RareCan Limited
weareumi – 10th November – Go Further Investment Index Celebrates most Progressive Northern UK Businesses
EPM Magazine – 9th November – Blood Cancer UK Partners with RareCan to Improve Delivery of Clinical Trials
Technology Networks – 9th November – RareCan Receives Approval from NHS Research Ethics Committee to Establish Vital BioResource at Newcastle University
Northern Echo – 4th November – Teesside University New Cancer Treatment Research Partnership
PharmaTimes – 2nd November 2021 – Putting Digitally Empowered Patients at the Core of Rare Cancer Research
Drug Discovery World – 26th October 2021 – RareCan Receives approval to establish BioResource at Newcastle University
Newcastle Chronicle – 5th October 2021 – Newcastle professor’s ‘matchmaking’ site helps patients with rare cancers find the clinical trials that could save their lives
Pharmafile – 25th August 2021 – RareCan appoints Dr Anita Cooper
Drug Discovery World – 4th August 2021 – Appointment strenghtens the experience of RareCanG
RareCan appoints Raj Sharma as Chief Technology Officer
Hexham, UK, April 2022: RareCan, a direct-to-patient clinical trial recruitment platform bringing together the power of patients and their data to reduce the costs of
RareCan partners with Blood Cancer UK to accelerate research into rare cancers
Hexham, UK, 08 November 2021: RareCan, a novel company accelerating research into rare cancers, today announced it has partnered with leading UK-based charity, Blood Cancer
RareCan receives approval from NHS Research Ethics Committee to establish vital BioResource at Newcastle University
RareCan receives approval from NHS Research Ethics Committee to establish vital BioResource at Newcastle University Hexham, UK, 25 October 2021: RareCan, a novel company accelerating
RareCan appoints Dr Anita Cooper as Non-Executive Director
RareCan appoints Dr Anita Cooper as Non-Executive Director Hexham, UK, 2nd August 2021: RareCan, a new and innovative company accelerating research into rare cancers, today
Mandashi Invests in RareCan
Mandashi Invests in RareCan We urgently need to increase treatment options and improve outcomes for people with rare cancer. At RareCan, we are working with
RareCan and NovoPath Partnership
NovoPath & RareCan Partnership Analysing samples from tumours lies at the heart of the discovery of new forms of treatment for cancer. Rare Cancers are
